Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omega-3 fatty acids + inositol + N-acetyl cysteine is a combination of natural supplements being evaluated by the Child Mind Institute for the treatment of emotional dysregulation in children and adolescents with Autism Spectrum Disorder (ASD) or non-verbal learning disability (NVLD). The intervention involves three distinct components: omega-3 fatty acids, which are believed to exert anti-inflammatory effects and modulate cell membrane fluidity; inositol, which acts as a precursor for the phosphatidylinositol second messenger signaling system; and N-acetyl cysteine (NAC), an antioxidant that serves as a precursor to glutathione and modulates glutamatergic neurotransmission. A 6-week open-label randomized clinical trial was conducted to compare the efficacy and tolerability of these agents in managing mood swings and emotional outbursts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 fatty acids + inositol + N-acetyl cysteine.